The State of Innovation in Drug Development

Abstract

The pharmaceutical industry is facing tremendous pressure, not only from payers but as a result of public perception, regulatory hurdles, and the intricacies of research and development (R&D). The latter two are significant in that they affect the number of drugs that may be registered by regulatory authorities, the time to discover and develop drugs, and the cost of drug development. Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation. Failure to innovate drug development will render the "big pharma" model unsustainable.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 276 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.